title: Cyclosporine inhibits profibrotic effects of interleukin-4 and transforming growth factor β on human intrahepatic fibroblasts cultured in vitro.
abstract: BACKGROUND
  Hepatic fibrosis, an outcome of chronic liver diseases, is characterized by an accumulation of collagen, which is produced by activated human intrahepatic fibroblasts (HIF). Transforming growth factor (TGF) β is an important inducer of fibrogenesis, in collaboration with other cytokines, such as interleukin (IL) 4. IL-4 is overexpressed in severe recurrent hepatitis C after liver transplantation, exerting profibrotic effects. In contrast, cyclosporine (CsA) had been shown to decrease fibroblast activation and collagen production. We therefore investigated the effects of CsA on TGF-β and IL-4 profibrotic activities on HIF in vitro.
  
  
  METHODS
  Isolated HIF were cultured without or with human TGF-β, human IL-4, CsA, or combined TGF- β+CsA or IL-4+CsA. We performed real-time polymerase chain reaction for collagen types I, III, and IV and alpha-SMA, a marker of fibroblast activation we also measured total collagen in supernates. TGF-β and IL-4 increased the expressions of alpha smooth muscle action (SMA) collagen I, III, and IV mRNAs (P < .05 vs untreated cells) as well as the overall collagen level in the supernates (P < .01). CsA decreased the expression of mRNAs encoding alpha-SMA and collagens (P < .01). Expressions of alpha-SMA and collagens I, III, and IV mRNAs were significantly lower under combined treatments (TGF-β vs TGF-β+CsA [P < .01] and IL-4 vs IL-4+CsA [P < .01]). Collagen level was decreased by combined treatments (TGF-β vs TGF-β+CsA [P < .05] and IL-4 vs IL-4+CsA [P = .05]).
  
  
  CONCLUSIONS
  CsA inhibited the profibrotic effects of TGF-β and IL-4 by decreasing the activation and production of collagen by HIF. CsA may decrease fibroblast activation and collagen accumulation, exerting beneficial effects on fibrosis progression, particularly among patients with recurrent hepatitis C.
authors.affiliation: Inserm UMR 938, IFR 65, Université Paris 6, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Pissaia
authors.forename: L
authors.initials: L
authors.lastname: Aoudjehane
authors.forename: S
authors.initials: S
authors.lastname: Ben Othman
authors.forename: O
authors.initials: O
authors.lastname: Scatton
authors.forename: O
authors.initials: O
authors.lastname: Soubrane
authors.forename: C
authors.initials: C
authors.lastname: Housset
authors.forename: Y
authors.initials: Y
authors.lastname: Calmus
authors.forename: F
authors.initials: F
authors.lastname: Conti
mesh_terms: D002478:Cells, Cultured; D003094:Collagen / Q000235:genetics; D016572:Cyclosporine / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects; D005355:Fibrosis; D006801:Humans; D066298:In Vitro Techniques; D015847:Interleukin-4 / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D008099:Liver / Q000166:cytology / Q000187:drug effects*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000494:pharmacology
chemical_list: D016212:Transforming Growth Factor beta; D015847:Interleukin-4; D016572:Cyclosporine; D003094:Collagen